FDA grants breakthrough therapy status to MSK ’s Burtomab neuroblastoma therapy

Memorial Sloan Kettering Cancer Center (MSK)-developed Burtomab has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of pediatric patients with relapsed or refractory neuroblastoma with centra … (Source: Pharmaceutical Technology)

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2s15XCq
via IFTTT